All In Biotech

Drug Trial Radar · NCT05147233

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 241 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

241

Actual

Start

Jun 24, 2022

Primary completion

Jun 22, 2023

Study completion Jul 3, 2023

Sponsor

Lead sponsor
OculisIndustry
Sponsor type
Industry
First posted
Dec 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.

Conditions

  • Inflammation Eye Pain
  • Postoperative Cataract

Interventions

  • OCS-01Drug

    Dexamethasone ophthalmic suspension, 1.5%

  • VehicleDrug

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absence of Anterior Chamber Cells at Visit 6.Time frame: Day 15
  2. Absence of Ocular Pain at Visit 4.Time frame: Day 4

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Oculis Site 16

    Chandler, Arizona

  • Oculis Site 28

    Phoenix, Arizona

  • Oculis Site 8

    Fayetteville, Arkansas

  • Oculis Site 9

    Inglewood, California

  • Oculis Site 23

    Newport Beach, California

  • Oculis Site 26

    Petaluma, California

  • Oculis Site 24

    San Pedro, California

  • Oculis Site 22

    Westminster, California

  • Oculis Site 11

    Fort Collins, Colorado

  • Oculis Site 12

    Tamarac, Florida

  • Oculis Site 17

    Morrow, Georgia

  • Oculis Site 20

    Louisville, Kentucky

  • Oculis Site 5

    St Louis, Missouri

  • Oculis Site 3

    Washington, Missouri

  • Oculis Site 13

    Kinston, North Carolina

  • Oculis Site 6

    Brecksville, Ohio

  • Oculis Site 14

    Cincinnati, Ohio

  • Oculis Site 25

    Eugene, Oregon

  • Oculis Site 7

    Kingston, Pennsylvania

  • Oculis Site 4

    Austin, Texas

  • Oculis Site 10

    Houston, Texas

  • Oculis Site 2

    San Antonio, Texas

  • Oculis Site 31

    San Antonio, Texas

  • Oculis Site 27

    Salt Lake City, Utah

  • Oculis Site 30

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.